» Articles » PMID: 23307170

A Semi-mechanistic Model of the Relationship Between Average Glucose and HbA1c in Healthy and Diabetic Subjects

Overview
Publisher Springer
Specialty Pharmacology
Date 2013 Jan 12
PMID 23307170
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

HbA1c is the most commonly used biomarker for the adequacy of glycemic management in diabetic patients and a surrogate endpoint for anti-diabetic drug approval. In spite of an empirical description for the relationship between average glucose (AG) and HbA1c concentrations, obtained from the A1c-derived average glucose (ADAG) study by Nathan et al., a model for the non-steady-state relationship is still lacking. Using data from the ADAG study, we here develop such models that utilize literature information on (patho)physiological processes and assay characteristics. The model incorporates the red blood cell (RBC) aging description, and uses prior values of the glycosylation rate constant (KG), mean RBC life-span (LS) and mean RBC precursor LS obtained from the literature. Different hypothesis were tested to explain the observed non-proportional relationship between AG and HbA1c. Both an inverse dependence of LS on AG and a non-specificity of the National Glycohemoglobin Standardization Program assay used could well describe the data. Both explanations have mechanistic support and could be incorporated, alone or in combination, in models allowing prediction of the time-course of HbA1c changes associated with changes in AG from, for example dietary or therapeutic interventions, and vice versa, to infer changes in AG from observed changes in HbA1c. The selection between the alternative mechanistic models require gathering of new information.

Citing Articles

A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes.

Sokolov V, Yakovleva T, Stolbov L, Penland R, Boulton D, Parkinson J CPT Pharmacometrics Syst Pharmacol. 2023; 12(6):831-841.

PMID: 36912425 PMC: 10272306. DOI: 10.1002/psp4.12956.


Optimization of trial duration to predict long-term HbA1c change with therapy: A pharmacometrics simulation-based evaluation.

Kunina H, Al-Mashat A, Chien J, Garhyan P, Kjellsson M CPT Pharmacometrics Syst Pharmacol. 2022; 11(11):1443-1457.

PMID: 35899461 PMC: 9662199. DOI: 10.1002/psp4.12854.


Pharmacometrics Approaches and its Applications in Diabetes: An Overview.

Aziz S, Harun S, Syed Sulaiman S, Sheikh Ghadzi S J Pharm Bioallied Sci. 2022; 13(4):335-340.

PMID: 35399800 PMC: 8985840. DOI: 10.4103/jpbs.jpbs_399_21.


A novel integrated QSP model of in vivo human glucose regulation to support the development of a glucagon/GLP-1 dual agonist.

Bosch R, Petrone M, Arends R, Vicini P, Sijbrands E, Hoefman S CPT Pharmacometrics Syst Pharmacol. 2021; 11(3):302-317.

PMID: 34889083 PMC: 8923724. DOI: 10.1002/psp4.12752.


Prior information for population pharmacokinetic and pharmacokinetic/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine.

Chan Kwong A, Calvier E, Fabre D, Gattacceca F, Khier S J Pharmacokinet Pharmacodyn. 2020; 47(5):431-446.

PMID: 32535847 PMC: 7520416. DOI: 10.1007/s10928-020-09695-z.


References
1.
Hempe J, Gomez R, McCarter Jr R, Chalew S . High and low hemoglobin glycation phenotypes in type 1 diabetes: a challenge for interpretation of glycemic control. J Diabetes Complications. 2002; 16(5):313-20. DOI: 10.1016/s1056-8727(01)00227-6. View

2.
Nathan D, Singer D, Hurxthal K, Goodson J . The clinical information value of the glycosylated hemoglobin assay. N Engl J Med. 1984; 310(6):341-6. DOI: 10.1056/NEJM198402093100602. View

3.
Gisleskog P, Karlsson M, Beal S . Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2003; 29(5-6):473-505. DOI: 10.1023/a:1022972420004. View

4.
Virtue M, Furne J, Nuttall F, Levitt M . Relationship between GHb concentration and erythrocyte survival determined from breath carbon monoxide concentration. Diabetes Care. 2004; 27(4):931-5. DOI: 10.2337/diacare.27.4.931. View

5.
Jonsson E, Karlsson M . Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999; 58(1):51-64. DOI: 10.1016/s0169-2607(98)00067-4. View